Synthesis and evaluation of analgesic, anti-inflammatory, and anticancer activities of new pyrazole-3(5)-carboxylic acid derivatives

Crystal structure of N′-(4-(dimethylamino)benzylidene)-5-phenyl-1H-pyrazole-3-carbohydrazide, C19H19N5O

“…These derivatives show broad spectrum activity such as anti-in ammatory [1], anti-oxidant [2], antipyretic [3], antimicrobial [4], antiviral [5], anticancer [6], antitumor [7], anticonvulsant [8], analgesic [9], antidepressant [10], insecticides and fungicides [11,12]. For this title structure, the asymmetric unit contains two independent molecules ( gure).…”

Crystal structure and Hirshfeld surface analysis of 1-(2,4-dichlorobenzyl)-5-methyl-N-(thiophene-2-sulfonyl)-1H-pyrazole-3-carboxamide

“…The pyrazole core structure has been widely used as a common heterocyclic scaffold in medicinal chemistry to produce novel drug candidates with a great variety of pharmacological activities including anti-inflammatory, antiplatelet, anticancer, antimycobacterial, antidepressant and anticonvulsant properties (Kü çü kgü zel & Ş enkardeş, 2015;Ç alışkan et al, 2013;Ding et al, 2009;Baraldi et al, 2004;Palaska et al, 2008). Among them, pyrazole-carboxamide derivatives have been shown to exhibit antimycobacterial, antifungal and antiviral activities (Sun & Zhou, 2015;Yan et al, 2018;Comber et al, 1992).…”

Design, synthesis, molecular docking and biological evaluation of novel 1,5-diarylpyrazole-N,O-dimethyl hydroxamate derivatives as antiproliferative agents.

“…Pyrazoles are an important class of heterocyclic compounds and exhibit broad range of biological activities including antiinflammatory, antimicrobial, antioxidant, and anticancer activities [9][10][11]. Biological evaluation indicated that some pyrazole containing compounds exhibited antiproliferative activity against human cervical cancer cell line Hela by inhibition of Hela cell migration and potent EGFR tyrosine kinase inhibitory activity such as compounds I, II, III, IV and V (Fig 1) with IC50 values of 0.07, 0.24, 0.06, 0.26 and 0.12 µM, respectively in comparison to a positive control erlotinib (IC50 = 0.03 µM).…”